|
Variable
|
All (n = 124)
|
Non-PD (n = 44)
|
PD (n = 80)
|
P
|
|---|
|
Age (year)
|
61 ± 11
|
62 ± 10
|
61 ± 12
|
0.707
|
|
Sex, N (%)
|
107 (86.3)
|
36 (81.8)
|
71 (88.8)
|
0.423
|
|
ECOG performance status 0, N (%)
|
112 (90.3)
|
42 (95.5)
|
70 (87.5)
|
0.210
|
|
Etiology, N (%)
| | | |
0.02
|
|
HBV
|
91 (73.4)
|
26 (59.1)
|
65 (81.2)
| |
|
HCV
|
21 (16.9)
|
10 (22.7)
|
11 (13.8)
| |
|
Alcohol
|
12 (9.7)
|
8 (18.2)
|
4 (5)
| |
|
Body mass index (kg/m2)
|
22.3 ± 3.1
|
23.1 ± 3.2
|
21.9 ± 3.0
|
0.052
|
|
Macrovascular invasion, N (%)
|
39 (31.5)
|
11 (25.0)
|
28 (35.0)
|
0.344
|
|
Extrahepatic spread, N (%)
|
53 (42.7%)
|
16 (36.4)
|
37 (46.2)
|
0.382
|
|
BCLC stage C, N (%)
|
83 (66.9%)
|
25 (56.8)
|
58 (72.5)
|
0.185
|
|
Child-Pugh score, N (%)
| | | |
0.492
|
|
5
|
114 (91.9)
|
42 (95.5)
|
72 (90)
| |
|
6
|
10 (8.1)
|
2 (4.5)
|
8 (10)
| |
|
MELD
|
8.8 ± 2.2
|
8.36 ± 1.54
|
8.96 ± 2.47
|
0.1
|
|
Albumin (g/dL)
|
3.79 ± 0.42
|
3.78 ± 0.46
|
3.81 ± 0.41
|
0.739
|
|
Total bilirubin (mg/dL)
|
1.06 ± 0.50
|
0.99 ± 0.47
|
1.09 ± 0.51
|
0.273
|
|
Prothrombin time (INR)
|
1.14 ± 0.10
|
1.13 ± 0.09
|
1.15 ± 0.1
|
0.299
|
|
Creatinine (mg/dL)
|
0.89 ± 0.56
|
0.87 ± 0.13
|
0.9 ± 0.69
|
0.705
|
|
Platelet (×103/μL)
|
122 (17–787)
|
113 (17–291)
|
128 (52–787)
|
0.006
|
|
Alpha-fetoprotein (ng/mL)
|
128.8 (1.3–730,000)
|
114.7 (2.6–226,100)
|
152.2 (1.3–730,000)
|
0.187
|
|
PIVKA-II (mAU/mL)
|
109.5 (12–339,858)
|
25.5 (12–25,884)
|
351 (15–339,858)
|
0.003
|
|
Angiopoietin 2 (ng/mL)
|
2962.7 (1099.4–12,907.8)
|
2762.2 (1289.6–8360.4)
|
3026.9 (1099.4–12,907.8)
|
0.109
|
|
CD117 (ng/mL)
|
3.76 (1.01–226.85)
|
3.36 (1.01–10.23)
|
3.87 (1.10–226.85)
|
0.234
|
|
bFGF (pg/mL)
|
2.38 (0–61.57)
|
1.65 (0–14.62)
|
3.07 (0.43–61.57)
|
< 0.001
|
|
HGF (pg/mL)
|
1781.9 (913.9–6116.0)
|
1605.7 (913.9–4152.4)
|
1965.2 (1020.3–6117.0)
|
0.056
|
|
LOXL2 (ng/mL)
|
0.816 (0.034–4.007)
|
0.718 (0.034–4.007)
|
0.850 (0.039–3.765)
|
0.792
|
|
PDGFRb (pg/mL)
|
2045.6 (647.5–22,904.5)
|
2087.9 (777.7–22,904.5)
|
1965.3 (647.5–8214.9)
|
0.419
|
|
sVEGFR1 (ng/mL)
|
0.16 (0.04–13.65)
|
0.16 (0.06–13.65)
|
0.14 (0.04–0.53)
|
0.314
|
|
AAR
|
1.29 (0.58–11.6)
|
1.31 (0.58–2.67)
|
1.29 (0.61–11.6)
|
0.105
|
|
APRI
|
1.01 (0.17–6.54)
|
1.17 (0.17–4.54)
|
0.95 (0.17–6.54)
|
0.847
|
|
FIB-4
|
4.0 (0.6–21.0)
|
4.4 (0.9–21.0)
|
3.6 (0.6–12.3)
|
0.161
|
|
Lok index
|
0.66 ± 0.24
|
0.67 ± 0.24
|
0.65 ± 0.24
|
0.68
|
|
P2/MS
|
29.6 (0.46–1060.7)
|
27.3 (0.5–202.4)
|
36.7 (6.2–1060.7)
|
0.102
|
- Values are expressed as mean ± standard deviation, medians (ranges), or frequencies (percentages)
- Abbreviations: PD, progressive disease, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4
